Bioavailability of Diosmin/Hesperidin (90/10) 500 mg Tablets With Regards to Reference Product

Bioequivalence Clinical Trial

Official title:

Bioavailability of a Formulation of Diosmin/Hesperidin (90/10) 500 mg Tablets With Regards to the Marketed Reference Product

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05158192
• Other study ID #: HP8834-01
• Status: Completed
• Phase: Phase 1
• Start date: November 4, 2021
• Est. completion date: December 14, 2021

Study information

• Verified date: November 2021
• Source: Laboratorios Andromaco S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Pilot study investigated the bioavailability in adult human subjects of 1 tablet formulations containing Diosmin/Hesperidin (90/10) 500 mg. The Pilot study was performed at a single site with 12 subjects. Participants took 1 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There was a washout of 7 days between each study period.

Description:

The primary objective of the study is to investigate the relative bioavailability of

Diosmin/Hesperidin (90/10) of 1 tablet formulations with Diosmin/Hesperidin (90/10) 500 mg to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:

• Test Product: Product manufactured by Laboratorios Andrómaco S.A.

• Reference Product: Daflon [Trademark], product of Les Laboratoires Servier, France.

The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters area under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to infinite (AUC0-inf), and maximum plasma concentration (Cmax) for total metabolite Diosmetin and Hesperetin was determined. Participants were confined in the study site for approximately 42 hours during each study period (for 10 hours pre-dosing and for 32 hours post dosing) during which pharmacokinetic (PK) blood samples were obtained. 21 blood samples were taken up to 32 hours after the administration in each period. Participants returned to the site to provide additional blood samples at 48 h, and 72 h postdose. The washout period between the two study periods was 7days. The samples from each participant were analyzed with validated LC-MS/MS method used for estimation of Diosmetin and Hesperetin in plasma.

The safety objective was to evaluate the tolerability of both formulations in subjects by collecting adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: December 14, 2021
• Est. primary completion date: December 14, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy male and/or non-pregnant, non-breast feeding female literate volunteers of 18 to 45 years (both years inclusive) with BMI of 18.50 - 29.99 Kg/m2 and weight > 50 Kg.

2. Healthy volunteers as evaluated by medical history, vitals and general clinical examination.

3. Normal or clinically insignificant biochemical, hematological, urine and serology parameters.

4. Normal or clinically insignificant ECG.

5. Negative urine test for drugs of abuse for both males and females and negative pregnancy test for females and do not plan to become pregnant during course of the study and for 03 months after completion of study.

6. Volunteers who are willing to use acceptable methods of contraception (barrier method/IUD/surgical) or abstinence, for the entire duration of the study and do not plan to be pregnant for atleast 1 month after the last drug administration.

7. Volunteers who can give written informed consent and communicate effectively.

Exclusion Criteria:

1. History of any major surgical procedure in the past 03 months.

2. History of any clinically significant cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric and hematological disorders.

3. History of chronic alcoholism/ chronic smoking/ drug of abuse.

4. Volunteers with known hypersensitivity to Diosmin/Hesperidin or any of the excipients.

5. History of consumption of tobacco containing products within 48 hours prior to proposed time of dosing

6. Volunteers who are positive for hepatitis B surface antigen, anti-hepatitis C antibody, treponemal antibodies and human immunodeficiency virus (HIV 1&2) antibodies.

7. Present or past history of intake of drugs or any prescription drug or over the counter (OTC) drugs within 14 days which potentially modify kinetics / dynamics of Diosmin/Hesperidin or any other medication judged to be clinically significant by the investigator.

8. History of consumption of grapefruit and/or its products within 10 days prior to the start of study.

9. Volunteers who had participated in any other clinical study or who had bled during the last 03 months before check-in.

10. History of consumption of one or more of the below, 48 hours prior to dosing: Xanthine containing food or drinks such as cola, chocolate, coffee or tea, citrus fruits or items (lime, lemon and orange), alcohol and any other food/beverage known to have interactions as deemed by the investigator

11. Volunteers who are dysphagic.

Related Conditions & MeSH terms

• Bioequivalence

Intervention

Drug:
• Diosmin/Hesperidin (90/10) 500 mg Test Drug
Investigational Medicinal Product
• Diosmin/Hesperidin (90/10) 500 mg Reference Product
Daflon (Trademark)

Locations

Country	Name	City	State
India	Azidus Laboratories Ltd.	Chennai	Tamil Nadu

Sponsors (1)

Lead Sponsor	Collaborator
Laboratorios Andromaco S.A.

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Diosmin/Hesperidin (90/10): area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)	23 samples up to 72 hours will be taken after the administration in each period.	From tablet intake and up to 72 hours after tablet intake
Primary	Total Diosmin/Hesperidin (90/10): area under the plasma concentration-time curve from 0 to t hours (AUC0-t)	23 samples up to 72 hours will be taken after the administration in each period.	From tablet intake and up to 72 hours after tablet intake
Primary	Total Diosmin/Hesperidin (90/10): Maximum plasma concentration (Cmax)	23 samples up to 72 hours will be taken after the administration in each period.	From tablet intake and up to 72 hours after tablet intake